Sandoz, A Novartis Division
So just firstly, with Kisqali, you previously recommended that adjuvant is a $6 billion chance. Simply because when you look at the epidemiology, it would recommend a substantially bigger opportunity in intermediate pension pool. So, I am just curious what assumptions you happen to be generating in terms of which — basically get the drug in this population since genuinely, if you see a decent penetration, the marketplace prospective need to be significantly larger. Just on sabatolimab, offered the delay…